Skip to content

Risk of VTE and adverse pregnancy in women with Inherited thrombophilia

Risk of VTE and adverse pregnancy in women with Inherited thrombophilia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084979
Enrollment
Unknown
Registered
2024-05-29
Start date
2024-05-31
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inherited thrombophilia

Interventions

hereditary thrombophilia group:Not applicable

Sponsors

Fujian Maternity and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: (1) Antithrombin deficiency (<60%) (2) Protein C deficiency (<65%) (3) Protein S deficiency (<55%) (4) Prothrombin F2 deficiency (5) FV mutation (6) Gestational age less than 7 weeks (7)No anticoagulant medication used

Exclusion criteria

Exclusion criteria: 1: Women with anatomical genital anomalies clearly diagnosed by ultrasound or hysterosalpingography 2: Couples or embryos with chromosomal abnormalities 3: Women with a history of taking teratogenic drugs early in pregnancy 4: Systemic or localized immune abnormalities of the reproductive tract (e.g., antiphospholipid syndrome) 5: Ongoing use of anticoagulants such as heparin analogs, warfarin, direct oral anticoagulants, etc. 6. Over 35 years of age

Design outcomes

Primary

MeasureTime frame
venous thromboembolism;

Secondary

MeasureTime frame
abortion;prematurity;Smaller than gestational age;pre-eclampsia;eclampsia;HELLP syndrome;abruption of the placenta;stillbirth;

Countries

China

Contacts

Public ContactZhang Jinhua

Fujian Maternity and Child Health Hospita

pollyzhang2006@126.com+86 133 0691 2381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026